SecBot SecBot
Biotech Drug Report Generated Aug 29, 2026

PREVYMIS

MRK·Merck & Co., Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Approved (for CMV prophylaxis in HSCT). Phase 2 completed for lung transplant indication (NCT05041426).
Time to market
Already approved and commercially available (FDA approval November 8, 2017). Additional indications may be pursued but no near-term timeline is defined.
Why 2/10
No upcoming PDUFA, pivotal readout, or binary catalyst for PREVYMIS in the next ~12 months. The drug was approved in November 2017 and is a mature commercial product within Merck's vast portfolio. ImpactScore is 2 because the drug carries no near-term defined catalyst to move MRK shares and is a very small part of a mega-cap diversified pharma company.
⚠ Few sources Few sources were found for this drug. Treat the rating as low-confidence and verify against the cited sources.
Actionable Insight NEUTRAL

PREVYMIS is already approved and commercialized; there is no upcoming PDUFA, pivotal readout, or binary catalyst for this drug in the next 12 months. For MRK investors, PREVYMIS is a negligible standalone consideration. Focus instead on Merck's upcoming KEYTRUDA PDUFA dates (September 21, 2026) and the ifinatamab deruxtecan PDUFA (October 10, 2026) for material catalysts.

Price Chart

Loading chart...

Executive Summary

PREVYMIS (letermovir) is an FDA-approved antiviral drug from Merck & Co. (MRK) for preventing cytomegalovirus (CMV) infection in adult stem-cell transplant recipients. Approved in November 2017, it is a marketed commercial product with no pending regulatory decisions. As one of many products in Merck's massive, diversified portfolio (dominated by KEYTRUDA), PREVYMIS is not a material stock-moving catalyst for MRK, the stock's value is driven by the broader pipeline including upcoming KEYTRUDA label-expansion PDUFA dates and other high-impact assets.

How It Works

PREVYMIS is an antiviral medication that blocks CMV (a common herpes-type virus) from replicating by interfering with the virus's ability to package its DNA into new virus particles. It works differently from older CMV drugs (like ganciclovir) and is less toxic to bone marrow, which is important for transplant patients whose marrow is already stressed.

Trial Status

PREVYMIS was approved by the FDA on November 8, 2017 for prophylaxis of CMV infection in adult CMV-seropositive allogeneic HSCT recipients. An investigator-sponsored Phase 2 trial (NCT05041426) studying letermovir for CMV prevention after lung transplantation completed in March 2025 with results available.

The Two-Sided Case

▲ Bull Case3
PREVYMIS fills a specific niche as a CMV terminase inhibitor with a novel mechanism, less bone-marrow toxicity than conventional therapies like ganciclovir, making it a preferred option for post-transplant prophylaxis where marrow recovery is critical.
A completed Phase 2 trial (NCT05041426) studying letermovir for CMV prevention after lung transplantation (March 2025 completion) suggests potential label expansion into additional solid-organ transplant indications, which could incrementally grow the product's addressable market.
As an approved, commercially available drug with a clean safety profile, PREVYMIS generates steady recurring revenue for Merck with no binary clinical risk.
▼ Bear Case3
PREVYMIS is a minor revenue contributor within Merck's massive portfolio, MRK's value is overwhelmingly driven by KEYTRUDA (~$25B+/year) and other oncology assets, not anti-infective products like PREVYMIS.
No upcoming PDUFA or label-expansion catalyst for PREVYMIS; the drug's commercial profile is mature and incremental growth from new indications (e.g., lung transplant prophylaxis) faces clinical and regulatory timelines unlikely to move Merck's stock materially.
Competing CMV antivirals like valganciclovir/ganciclovir remain standard-of-care alternatives, limiting PREVYMIS's market penetration upside.

Upcoming Catalysts

  • No upcoming PREVYMIS-specific catalysts identified. For MRK broadly: KEYTRUDA sBLA PDUFA (Sept 21, 2026), WELIREG sNDA PDUFA (Oct 4, 2026), ifinatamab deruxtecan sBLA PDUFA (Oct 10, 2026).

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Merck & Co., Inc. 8-K MRK ·Originating report

Sources · 1

Hover a chip for the title
1 sec.gov